Ebewe/Sandox has initiated a voluntary recall of certain lots of ebetraxate as a precautionary measure. See related file.

Due to a given occasion and due to inquiries regarding "innovations" in the field of traditional herbal medicinal products, the Federal Office for Safety in Health Care takes the liberty to inform about the current legal situation. The background of the current discussions is not a "new document" of the European Commission, but the transitional…

Ebewe/Santoz has initiated a voluntary recall of certain lots of 5-fluorouracil as a precautionary measure. See related file.

Notice of supply difficulties for PegIntron Powder and Solvent for Solution for Injection. See related file.

BASG/AGES PharmMed informs about the internal changeover of the E2B transmission of individual case reports, which was previously done via WebTrader, to gateway operation. The changeover will take place in October. For notifiers who have already successfully tested the electronic transmission of case reports to BASG or have already transmitted…

All eServices offered by BASG / AGES PharmMed will be available via this platform in the future. Currently, the following services can be accessed via the eServices navigation point: Non-interventional studies (NIS) : Public register of all NIS started in Austria as of 01.09.2010. Evaluations can be performed via the register and the result can be…

A notice from the Dutch government.

The Medicinal Products Import Act 2010, BGBl I 79/2010, came into force on 19.08.2010. Compilation of the scenarios possible according to the law and the forms to be used: AWEG 2010 scenarios import certificates.pdf AWEG 2010 scenarios marketability certificates.pdf AWEG 2010 scenarios movement certificates.pdf Note: Pursuant to Section 26(1) and…

On 18.08.2010, the Medicinal Products Import Act 2010 was published in the Federal Law Gazette, Federal Law Gazette I No. 79/2010 and comes into force on 19.08.2010. The primary objective of the Medicinal Products Import Act is to protect the health of patients and consumers by ensuring safe, high-quality and effective medicinal products. This goal…

The Federal Office for Safety in Health Care (BASG) publishes the following statement on "Calcium Supplementation and Myocardial Infarction Risk." It refers to a meta-analysis on the use of calcium as monotherapy for osteoporosis published in the British Medical Journal on July 29, 2010. (Bolland MJ. BMJ 2010;341:c3691…